Covered topics - NAFLD pathogenesis, patient management, prognostic and therapeutic targets, non-invasive assessment of fibrosis, apoptosis, biomarkers, insulin resistance and signalling, hormonal and bile acids signalling, oxidative and mitochondrial stress, inflammation and immunity in NASH, carcinogenesis, gut microbiota.


Dear colleagues,

We would like to cordially invite you to the First EASL Nonalcoholic Fatty Liver Disease (NAFLD) Summit: Target-oriented approach to Diagnosis and Pharmacotherapy of Nonalcoholic Steatohepatitis (NASH), a dialogue between Academia and Industry’ to be held on the 9 to 11 November 2017 in Rome, Italy.

NAFLD is the leading cause of chronic liver disease not only in Western countries but also among developing countries of the Far East, South Asia, the Middle East, and Latin America. In the US and Europe, nearly 40% of the population have NAFLD and approximately 20% of these individuals are likely to develop progressive liver disease (i.e. NASH) that leads to liver fibrosis and cirrhosis. Another emerging challenge is hepatocellular cancer, which increasingly arises in precirrhotic stages. Although a significant number of new drugs are already in the development pipeline, none are as yet, approved by regulatory agencies.  As such, the identification and development of new therapies is urgently needed.

This summit will cover both the basic and translational / clinical aspects of NAFLD, with a specific focus on novel drug target and prognostic signature development.

Key sessions include all crucial pathophysiological aspects currently known to affect development and progression of NAFLD, such as "lipid metabolism and lipotoxicity" and "insulin resistance, insulin and hormonal signaling". Furthermore, oxidative stress, ER stress, and mitochondrial dysfunction will be addressed. On the second day, inflammation, adaptive and innate immunity as well as apoptosis and microparticles will be discussed in the NAFLD context. Moreover, bile acids and bile acid signaling as well as gut microbiota will be covered. Finally, key aspects of hepatic fibrosis and carcinogenesis in relation to NAFLD will be addressed.

Unlike other NAFLD meetings, this inaugural summit will feature a significant representation by industry partners and presentations will be delivered by both academia and industry leaders to stimulate our joint efforts in addressing the key challenges across the spectrum of NAFLD.
In each of these sessions, an academic overview by an eminent physician-scientist will be followed by 3 to 4 state-of-the-art presentations on the current research landscape and translational advances. Active audience participation will be encouraged, with the aim of fostering greater research collaborations between academia and industry. In addition, there will be the opportunity to submit abstracts of ongoing basic and translational research, and these will be accepted as e-posters.

We anticipate that this combination of high quality and interactive presentations by leading scientist and clinicians from academia and industry will bring together various stake holders with an interest in NAFLD care, service, and research.

We look forward to welcoming you to Rome for this major event.

The Scientific Committee


HELLEBRAND.jpg SYN.jpg Trauner.jpg

Prof. Ali Canbay

Prof. Claus Hellerbrand

Prof. Wing-Kin Syn

Prof. Michael Trauner

Germany Germany United States Austria


Targeted audience             Why attend?
  • Basic and translational scientists
  • Clinical researchers
  • Industry / Biotechnology
  • Hepatologists
  • Health professionals
  • Regulatory and funding agencies
  • Young researchers and trainees
  • Presentations from Academia and Industry
  • Dedication to translational science
  • Encouragement of collaboration between Academia and Industry
  • Identification of future areas for drug development

related news

EASL-AASLD experts and stakeholders identify potential directions to help combat alcoholic liver disease

First EASL NAFLD summit highlights current advances in the field of fatty liver disease

Key Deadlines


Up to & incl.
08 September 2017


10 September 2017

Registration is closed
View the online programme highlights or download PDF file.
Abstract submission was open up to & incl. 08 September 2017